Candidiasis in the Era of COVID-19: Challenges, Treatment Approaches,and Research Priorities

The advent of COVID-19 has significantly affected global healthcare systems, not only through the direct impact of SARS-CoV-2 but also by triggering an increase in opportunistic infections such as COVID-19-associated candidiasis (CAC). Critically ill patients, particularly those in Intensive Care Units (ICUs), are highly vulnerable due to prolonged hospitalization, mechanical ventilation, and the use of broad-spectrum antibiotics, corticosteroids, and immunosuppressive therapies. Candida auris has emerged as a high-priority pathogen. This review summarizes the interplay between SARS-CoV-2 infection and Candida colonization or invasion, highlighting key clinical and microbiological risk factors. Global epidemiological data show marked regional variation and a rising prevalence of non-albicans Candida species in ICUs across India, Iran, Europe, and the Americas. Clinically, CAC may present as persistent fever unresponsive to antibiotics or progress to systemic candidemia with multi-organ involvement. Diagnosis remains challenging due to symptom overlap with severe COVID-19. However, blood cultures remain standard; their low sensitivity necessitates adjunctive tools such as β-D-glucan assays, PCR-based methods, and radiological evaluation. Management involves early initiation of antifungal therapy, preferably echinocandins, along with supportive measures, including glycemic control, judicious use of immunosuppressants, and strict infection-control practices. Key research priorities include rapid diagnostics, novel antifungal agents, strategies targeting biofilms, and strengthened surveillance of antifungal resistance. In conclusion, CAC represents a serious emerging complication in COVID-19 care. Effective prevention and management require multidisciplinary efforts encompassing timely diagnosis, optimized treatment, and robust public-health interventions.